Literature DB >> 23115008

O-Mannosylation and human disease.

Christina M Dobson1, Samuel J Hempel, Stephanie H Stalnaker, Ryan Stuart, Lance Wells.   

Abstract

Glycosylation of proteins is arguably the most prevalent co- and post-translational modification. It is responsible for increased heterogeneity and functional diversity of proteins. Here we discuss the importance of one type of glycosylation, specifically O-mannosylation and its relationship to a number of human diseases. The most widely studied O-mannose modified protein is alpha-dystroglycan (α-DG). Recent studies have focused intensely on α-DG due to the severity of diseases associated with its improper glycosylation. O-mannosylation of α-DG is involved in cancer metastasis, arenavirus entry, and multiple forms of congenital muscular dystrophy [1, 2]. In this review, we discuss the structural and functional characteristics of O-mannose-initiated glycan structures on α-DG, enzymes involved in the O-mannosylation pathway, and the diseases that are a direct result of disruptions within this pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115008      PMCID: PMC3984002          DOI: 10.1007/s00018-012-1193-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  81 in total

Review 1.  Dystroglycan: from biosynthesis to pathogenesis of human disease.

Authors:  Rita Barresi; Kevin P Campbell
Journal:  J Cell Sci       Date:  2006-01-15       Impact factor: 5.285

2.  Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding.

Authors:  Stefan Kunz; Jillian M Rojek; Motoi Kanagawa; Christina F Spiropoulou; Rita Barresi; Kevin P Campbell; Michael B A Oldstone
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies.

Authors:  Prabhjit K Grewal; Jennifer M McLaughlan; Christopher J Moore; Claudia A Browning; Jane E Hewitt
Journal:  Glycobiology       Date:  2005-06-15       Impact factor: 4.313

4.  A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1).

Authors:  Jianmin Liu; Sherry L Ball; Yuan Yang; Pinchao Mei; Lei Zhang; Haining Shi; Henry J Kaminski; Vance P Lemmon; Huaiyu Hu
Journal:  Mech Dev       Date:  2006-02-03       Impact factor: 1.882

Review 5.  Defect in glycosylation that causes muscular dystrophy.

Authors:  Tamao Endo; Hiroshi Manya
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

6.  Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Authors:  Ute Hehr; Goekhan Uyanik; Claudia Gross; Maggie C Walter; Axel Bohring; Monika Cohen; Barbara Oehl-Jaschkowitz; Lynne M Bird; Ghiat M Shamdeen; Ulrich Bogdahn; Gerhard Schuierer; Haluk Topaloglu; Ludwig Aigner; Hanns Lochmüller; Jürgen Winkler
Journal:  Neurogenetics       Date:  2007-09-29       Impact factor: 2.660

7.  Role of non-raft cholesterol in lymphocytic choriomeningitis virus infection via alpha-dystroglycan.

Authors:  Waris A Shah; Huashan Peng; Salvatore Carbonetto
Journal:  J Gen Virol       Date:  2006-03       Impact factor: 3.891

8.  Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism.

Authors:  Eric M Vela; Lihong Zhang; Tonya M Colpitts; Robert A Davey; Judith F Aronson
Journal:  Virology       Date:  2007-08-14       Impact factor: 3.616

9.  Cellular entry of lymphocytic choriomeningitis virus.

Authors:  Jillian M Rojek; Mar Perez; Stefan Kunz
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

10.  Regulation of mammalian protein O-mannosylation: preferential amino acid sequence for O-mannose modification.

Authors:  Hiroshi Manya; Takehiro Suzuki; Keiko Akasaka-Manya; Hide-Ki Ishida; Mamoru Mizuno; Yasushi Suzuki; Toshiyuki Inazu; Naoshi Dohmae; Tamao Endo
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

View more
  26 in total

1.  Facile Chemoenzymatic Synthesis of O-Mannosyl Glycans.

Authors:  Shuaishuai Wang; Qing Zhang; CongCong Chen; Yuxi Guo; Madhusudhan Reddy Gadi; Jin Yu; Ulrika Westerlind; Yunpeng Liu; Xuefeng Cao; Peng G Wang; Lei Li
Journal:  Angew Chem Int Ed Engl       Date:  2018-05-18       Impact factor: 15.336

2.  Chemoenzymatic Assembly of Mammalian O-Mannose Glycans.

Authors:  Caicai Meng; Aniruddha Sasmal; Yan Zhang; Tian Gao; Chang-Cheng Liu; Naazneen Khan; Ajit Varki; Fengshan Wang; Hongzhi Cao
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-25       Impact factor: 15.336

Review 3.  The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy.

Authors:  Lance Wells
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

4.  Induction of Antibodies Directed Against Branched Core O-Mannosyl Glycopeptides-Selectivity Complimentary to the ConA Lectin.

Authors:  Sabine Stahl; Jin Yu; Oliver C Grant; Christian Pett; S Strahl; Robert J Woods; Ulrika Westerlind
Journal:  Chemistry       Date:  2017-02-16       Impact factor: 5.236

5.  Chemoenzymatic synthesis of α-dystroglycan core M1 O-mannose glycans.

Authors:  Yan Zhang; Caicai Meng; Lan Jin; Xi Chen; Fengshan Wang; Hongzhi Cao
Journal:  Chem Commun (Camb)       Date:  2015-06-23       Impact factor: 6.222

Review 6.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

7.  Possible role of sialylation of retinal protein glycans in the regulation of electroretinogram response in mice.

Authors:  Satpal Ahuja
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

Review 8.  Mannose metabolism: more than meets the eye.

Authors:  Vandana Sharma; Mie Ichikawa; Hudson H Freeze
Journal:  Biochem Biophys Res Commun       Date:  2014-06-12       Impact factor: 3.575

9.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

Review 10.  The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy.

Authors:  Jamie L Marshall; Yukwah Kwok; Brian J McMorran; Linda G Baum; Rachelle H Crosbie-Watson
Journal:  FEBS J       Date:  2013-05-13       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.